5 Key Takeaways

• 1

  An international panel of 45 IBD experts established consensus recommendations on corticosteroid use at the United European Gastroenterology Week 2025.

• 2

  The panel identified issues like inconsistent tapering and prolonged exposure that compromise trial validity and increase steroid-related risks.

• 3

  Recommendations include harmonizing tapering schedules and limiting corticosteroid exposure during induction to improve trial outcomes.

• 4

  The panel emphasized the need for standardized definitions of steroid-related endpoints to enhance comparability across trials.

• 5

  The required duration of corticosteroid withdrawal for defining corticosteroid-free remission was not resolved during the consensus process.